Abstract

AbbVie will report fiscal Q2 2026 results on July 31, 2026 Pre-MKt; investors will watch revenue, margins, and adjusted EPS to gauge momentum across immunology, neuroscience, oncology, and aesthetics.

Market Forecast

Consensus compiled from the company’s latest guidance and market estimates points to fiscal Q2 2026 revenue of 16.76 billion US dollars, an EBIT of 8.14 billion US dollars, and adjusted EPS of 3.60, with year-over-year growth of 11.54% for revenue, 23.40% for EBIT, and 24.84% for EPS. Forecasted year-over-year performance indicates a supportive product mix; margins are expected to trend higher, with gross margin likely near last quarter’s 71.88% and net profit margin tracking modest improvement from 4.63%. Immunology remains the principal revenue engine and is expected to show stable growth, supported by steady demand in rheumatology and dermatology. Neuroscience is the most promising segment in the near term, with rising uptake and contribution; revenue is anticipated around 2.88 billion US dollars with strong year-over-year improvement.

Last Quarter Review

Fiscal Q1 2026 came in solid: revenue reached 15.00 billion US dollars, gross profit margin was 71.88%, GAAP net profit attributable to the parent company was 6.95 million US dollars, net profit margin was 4.63%, and adjusted EPS was 2.65, with year-over-year growth of 12.43%. Net profit declined quarter over quarter by 61.73%, highlighting timing and mix factors against the period’s strong revenue growth. The main business mix was anchored by immunology at 7.29 billion US dollars, followed by neuroscience at 2.88 billion US dollars, oncology at 1.63 billion US dollars, aesthetics at 1.19 billion US dollars, other key products at 995.00 million US dollars, and additional revenue streams at 1.03 billion US dollars.

Current Quarter Outlook

Main Business: Immunology

Immunology is positioned to drive the quarter’s topline, with a diversified portfolio across rheumatology and dermatology sustaining demand. The forecasted revenue expansion of 11.54% at the consolidated level implies a healthy immunology trajectory, supported by consistent formulary access and stable prescription volumes. Margin flow-through from immunology should aid consolidated gross margin resilience near the prior quarter’s 71.88%, as manufacturing efficiencies and pricing discipline help offset cost inflation. While sampling and competitive dynamics can affect individual brands, the breadth of the franchise supports steady unit growth that underpins the revenue outlook.

Most Promising Business: Neuroscience

Neuroscience is poised for outperformance within AbbVie’s portfolio, with continued uptake expected to lift segment revenue toward 2.88 billion US dollars. The product mix offers a favorable balance of volume growth and sustained access, contributing incremental operating leverage. Year-over-year improvement implied by consensus suggests strong momentum, and the segment’s margin profile should complement consolidated EBIT growth of 23.40%. Monitoring payer dynamics and prescription trends will be crucial this quarter; stable access and adherence would support the forecast trajectory.

Stock Price Drivers This Quarter

Earnings quality will hinge on the relationship between revenue growth of 11.54% and the projected adjusted EPS of 3.60, indicating potential operating leverage from cost control and mix. Investors will focus on gross margin stability around 71.88% and any commentary on net margin improvement from the 4.63% baseline. Segment updates across immunology and neuroscience will be pivotal for sentiment; upside could materialize if volumes exceed expectations, while the stock may be sensitive to signs of pricing pressure or increased competition. Guidance for the remainder of fiscal 2026, including EPS cadence and capital allocation, could be a key secondary catalyst.

Analyst Opinions

The majority of recent institutional views are bullish, emphasizing improving earnings cadence and margin recovery. Analysts point to double-digit revenue growth of 11.54% and robust EBIT expansion of 23.40% as indicators of operating leverage and healthy product momentum. Several well-known firms highlight the attractiveness of neuroscience growth alongside sustained immunology contributions, framing an outlook supportive of adjusted EPS at 3.60 for the quarter. Commentary underscores watchpoints around pricing and payer dynamics, but consensus leans toward a constructive setup given the mix and efficiency trends.